Magnetic resonance imaging-apparent diffusion coefficient (MRI-ADC) and 68 gallium [68Ga]Ga-prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET) imaging can differentiate International Society of Urological Pathology (ISUP) grade 1 patients, with clinically nonsignificant prostate cancer, from ISUP grade 2+ patients, according to a study published online April 8 in Cancers.
Giacomo Feliciani, from IRCCS Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, and colleagues applied radiomics analysis to MRI-ADC and [68Ga]Ga-PSMA-11 PET to quantify tumor characteristics and predict ISUP grades in 28 patients. Predictive models based on imaging features were trained on 31 lesions to differentiate ISUP grade 1 patients from ISUP grade 2+ patients.
The researchers found that the best model based on [68Ga]Ga-PSMA-11 PET had prediction efficiency of 95 and 100 percent in the training and test phases, respectively; the best model based on MRI-ADC had efficiency of 100 percent in both phases. Prediction efficiency was 100 and 93 percent in the training and test phases, respectively, when employing both models.
“Preliminary results suggest that aside from the MRI-ADC average value, currently employed in clinical practice to assess lesion severity, other imaging biomarkers may provide complementary information for ISUP grade prediction, but further, broader studies are necessary to confirm these findings,” the authors write. “Both [68Ga]Ga-PSMA-11 PET and MRI-ADC imaging biomarkers showed to be complementary in ISUP grade assessment when employed together to build prediction models.”
Source: HealthDay News
